Phacilitate announces patient-centric agenda for its January 2023 Advanced Therapies Week conference in Miami
Appointment to further integrate BioSenic’s both cell therapy and autoimmune disease platforms under the responsibility of a new CMO and cross-pollinate the experiences of both teams to accelerate clinical progression
CellProthera expands clinical trial sites for phase IIb myocardial infarction study
London, UK, December 19, 2022 – Phacilitate, the member network connecting industry leaders across the advanced therapies industry, today announces the final agenda for its Advanced Therapies Week 2023 conference in Miami, USA.
Orgenesis achieves revenue of USD 8.0 million for the third quarter of 2022
Secures up to USD 50 million of funding from Metalmark Capital Partners expected to accelerate rollout of point-of-care services
Reduces operating expenses by 49 percent to achieve nearly breakeven income from operation for the third quarter of 2022
Immutep granted new patents in Japan and South Korea for first-in-class LAG-3 candidate, eftilagimod alpha in chemo-immunotherapy combination
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents
Immutep announces promising initial clinical data from INSIGHT-003 at SITC 2022
First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7 percent response rate and 90.9 percent disease control rate in first-line NSCLC patients
The triple combination therapy has been well tolerated and appears to be safe
Immutep announces compelling clinical results from Phase II trial utilizing its first-in-class soluble LAG-3 protein, eftilagimod alpha, in first-line NSCLC at SITC 2022 Annual Meeting.
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces compelling new clinical data from the TACTI-002 all-comer PD-L1 Phase II trial
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)
BioSenic provides update on its autoimmune disease platform based on ATO (arsenic trioxide)
The autoimmune disease platform has completed a successful phase IIb trial targeting cGVHD (chronic Graft vs Host Disease), with a demonstrated efficacy of more than 75 percent
Phase III is under preparation with expected accelerated examination by FDA
Other indications should follow with wider market potential, including lupus and systemic sclerosis
Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million
• New company’s pipeline enriched with serious inflammatory indications in addition to its original cell therapy asset
• New Chairman, Board Members and Management appointed 24,463,421 ALLOB subscription rights granted to all existing shareholders
Orgenesis secures up to USD 50 Million subsidiary-level investment from Metalmark Capital to accelerate growth of Point-of-Care services
Metalmark Capital Partners, a leading private equity firm with extensive expertise in the healthcare sector, today announced an investment partnership whereby Metalmark has agreed to make a growth investment of up to USD 50 million in Orgenesis
Immutep announces abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Initial data from INSIGHT-003 trial treating patients with various solid tumours with triple combination therapy of efti, anti-PD-1 therapy, and chemotherapy to be discussed at SITC
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer
Based on the encouraging Phase II clinical data for PD-L1 all-comers presented at ASCO 2022
Marks the second Fast Track designation issued by the FDA for eftilagimod alpha, offering the potential for expedited development and review
Immutep receives AUD 2.7 million research and development tax incentive from French government
The “Crédit d’Impôt Recherche” (CIR), meaning “Research Tax Credit”, is a French government tax incentive by which French companies conducting research and development activities in Europe can be reimbursed 30 percent of their eligible expenditure.
Immutep qualifies to receive the CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France.
Terumo Blood and Cell Technologies launches Quantum Flex bioreactor
Terumo Blood and Cell Technologies launches Quantum Flex bioreactor platform, one of the first systems that enables cell therapy commercialization from process development through manufacturing
Next-generation platform makes hollow-fiber perfusion technology commercially relevant and delivers advanced software to support cGMP
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides a clinical development update for its first-in-class LAG-3 antigen-presenting cell (APC) activator product candidate, eftilagimod alpha ("efti").
Minoryx‘s marketing authorization application for its lead candidate leriglitazone validated by EMA
Late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces that it has filed a Marketing Authorization Application (MAA) for its lead candidate leriglitazone to the European Medicines Agency (EMA)
Ori Biotech and CTMC partner to accelerate novel cell therapy delivery
Ori is a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc and MD Anderson Cancer Center, today announce a collaborative partnership to develop industrial manufacturing processes for cell therapies.
Immutep appoints LAG-3 pioneer, Frédéric Triebel to Board
Biotechnology company developing LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Frédéric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect.
ISCT issues response to US federal judge ruling on FDA regulation of cell and gene therapies
ISCT, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients' lives.
ISCT addresses manufacturing standardization, a critical issue constraining the CGT development pipeline
ISCT, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients' lives, today announces the publication of its key insights report from the 4th Annual ISCT Commercialization Signature Series event
Bone Therapeutics reports half year 2022 results
Bone Therapeutics acquires majority participation in Medsenic to derisk and broaden its therapeutic portfolio
Preparation of the Medsenic Phase III clinical trial with oral formulation following positive results from Phase II arsenic trioxide in the first-line treatment of cGvHD (chronic GvH)
Bone Therapeutics ALLOB’s Phase IIb interim results expected in H1 2023
Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma
Immutep is pleased to announce it has signed a Material Transfer Agreement (“Agreement”) with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland